Medivir
Medivir AB is a Swedish clinical-stage pharmaceutical company developing proprietary drug candidates for hepatocellular carcinoma (fostrox) and rare bone disorders (MIV-711), supplemented by out-licensed assets generating royalty and milestone income, with proprietary programs protected by multiple FDA/EMA orphan drug designations.
- Company typePublic
- Founded1988
- HeadquartersStockholm, Sweden
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Medivir does
Medivir AB (publ) is a Swedish clinical-stage pharmaceutical company founded in 1988 and headquartered in Huddinge, Sweden, listed on Nasdaq Stockholm's Small Cap segment under ticker MVIR. The company develops innovative therapies targeting areas of high unmet medical need, with a current research focus on oncology — specifically hepatocellular carcinoma (HCC) via its proprietary candidate fostroxacitabine bralpamide (fostrox) — and on rare bone disorders including osteogenesis imperfecta and Legg-Calvé-Perthes disease via MIV-711, a cathepsin K inhibitor. Fostrox is a liver-targeted oral prodrug of troxacitabine that selectively delivers a DNA polymerase inhibitor to liver tumors while sparing healthy hepatocytes, with patent protection extending to April 2041; MIV-711 is positioned as a potential first-in-class disease-modifying treatment for OI with dual effects on bone resorption and formation.
Medivir operates a hybrid business model combining proprietary drug development toward commercialization in specialty/rare-disease markets with limited prescriber bases and out-licensing of pipeline assets to larger partners for development and commercialization in broader indications. Revenue is generated through licensing royalties — primarily from GSK's sales of Xerclear/Zoviduo (cold sore treatment out-licensed in 2009) — and from milestone and royalty entitlements on out-licensed assets including remetinostat (Biossil Inc., up to USD 60M in potential milestones plus mid-single-digit royalties), MIV-701/VBX-1000 (Vetbiolix, veterinary periodontitis), MBLI/MET-X (INFEX Therapeutics), and USP-7 (Ubiquigent). The company has secured FDA Orphan Drug Designation for fostrox (HCC, 2020), FDA/EMA orphan and Rare Pediatric Disease Designations for MIV-711 across multiple indications (2025), and a clinical collaboration with Eisai to evaluate fostrox in combination with Lenvima in second-line HCC.
Medivir firmographics
Firmographics- Name
- Medivir
- Legal name
- Medivir AB (publ)
- Website
- https://medivir.com
- Company type
- Public
- Founded year
- 1988
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Medivir AB is a Swedish clinical-stage pharmaceutical company developing proprietary drug candidates for hepatocellular carcinoma (fostrox) and rare bone disorders (MIV-711), supplemented by out-licensed assets generating royalty and milestone income, with proprietary programs protected by multiple FDA/EMA orphan drug designations.
- Ownership category
- akta.pro rank
Medivir industry classification
Industry- Product category
- Pharmaceutical Drug Development
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
- akta.pro secondary industry
- Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)
Keywords
Where Medivir is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Medivir business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Royalties from Xerclear/Zoviduo: Medivir receives royalties on sales of Xerclear/Zoviduo from GlaxoSmithKline and fixed royalties from Shijiazhuang Yuanmai Biotechnology for Chinese sales.
- Remetinostat licensing deal milestones and royalties: Outlicensed remetinostat to Biossil Inc. with potential payments up to USD 60 million in milestones plus mid-single-digit percentage royalties on future net sales.
- MIV-701/VBX-1000 royalties: Medivir retains significant financial upside through future royalties on net sales from Vetbiolix partnership plus substantial share of potential partnership payments from third-party collaborations.
- MBLI/MET-X revenue sharing: Medivir is entitled to a share of potential future revenue from INFEX Therapeutics development of MET-X for resistant bacteria.
- USP-7 revenue sharing: Exclusive global license to Ubiquigent for USP-7 program with agreed revenue sharing upon successful development or commercialization.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Medivir product offering
Product offeringCore offering
Medivir is a clinical-stage pharmaceutical company that develops proprietary drug candidates in oncology and rare bone diseases, with lead assets fostrox (a liver-targeted nucleotide DNA polymerase inhibitor prodrug for hepatocellular carcinoma) and MIV-711 (a cathepsin K inhibitor for osteogenesis imperfecta and Legg-Calvé-Perthes disease). It also maintains a portfolio of out-licensed drug assets (Xerclear for labial herpes, Remetinostat for skin cancers, Birinapant for solid tumors, MBLI/MET-X for resistant bacteria, MIV-701/VBX-1000 for veterinary periodontitis, USP-7) that generate royalties and milestone payments from pharmaceutical partners.
Product overview
Medivir is a Swedish pharmaceutical company focused on developing innovative therapies in areas of high unmet medical need, primarily in oncology. The company's product portfolio consists of proprietary drug candidates in clinical development (fostrox for hepatocellular carcinoma and MIV-711 for osteogenesis imperfecta), projects available for licensing (Birinapant and USP-7), and outlicensed/commercialized products (Xerclear for herpes, MBLI/MET-X for infections, MIV-701 for canine periodontitis, and Remetinostat for skin cancers). Medivir operates either independently or through partnerships for drug development and commercialization.
Differentiator
Problem solved
Functional benefit
Products and services
- Fostroxacitabine bralpamide (fostrox) A liver-targeted oral nucleotide DNA polymerase inhibitor prodrug of troxacitabine that selectively delivers the active cell-killing compound to liver tumor cells while minimizing effects on normal liver cells. Being developed for second-line hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, and liver metastases, in combination with lenvatinib.
- MIV-711 An oral cathepsin K inhibitor being developed for osteogenesis imperfecta (OI/brittle bone disease), Legg-Calvé-Perthes disease (LCPD), and osteoarthritis. Has demonstrated cartilage preservation and reduction of bone erosion in a Phase II osteoarthritis study and is positioned as a potential first approved pharmacological treatment for OI.
- Birinapant An intravenous SMAC mimetic being developed for the treatment of solid tumors, intended to improve treatment response and prolong survival when combined with other pharmaceuticals. Out-licensed to IGM Biosciences.
- USP-7
Quantifiable outcome
- ORR of 24% with median DOR of 7 months in Phase 1b/2a fostrox + Lenvima study (21 patients)
- +5 more outcomes
Companies that use Medivir
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Medivir technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Medivir partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Biossil Inc.coreExclusive global licensing agreement for remetinostat development rights. Biossil, a Toronto-based AI-native drug developer, will develop remetinostat globally for cutaneous T-cell lymphoma and other skin cancers. Medivir entitled to up to USD 60 million in milestones plus mid-single-digit percentage royalties on future net sales.
- Korean Cancer Study Group / Dr. Hong-Jae ChoncoreCollaboration for FLEX-HCC investigator-initiated randomized phase 2 study. Dr. Chon serves as primary investigator. Study to be conducted at 8 centers in Korea evaluating fostrox + Lenvima vs Lenvima monotherapy in second-line advanced HCC.
- Eisai Co., Ltd.coreClinical trial collaboration and supply agreement for evaluating fostrox in combination with Lenvima (lenvatinib) in a randomized, phase 2b study in second-line advanced liver cancer patients.
- Ubiquigent LimitedminorExclusive global license granted for USP-7 preclinical research program. Ubiquigent to develop and commercialize all related substances in all therapeutic indications in exchange for revenue sharing with Medivir upon successful development or commercialization. Unfortunately, funding challenges have made it impossible for Ubiquigent to continue operations.
- IGM BiosciencesminorExclusive licensing agreement for birinapant. Birinapant is a SMAC mimetic for treatment of solid tumors, acquired from TetraLogic Pharmaceuticals in 2016.
- VetbiolixcoreOut-licensed MIV-701 (VBX-1000) for veterinary use in canine and feline periodontitis. Vetbiolix reported positive Proof-of-Concept results in April 2024 and published results in Frontiers in Veterinary Science in November 2025. Phase II study ongoing with results expected Q4 2026. Medivir retains significant financial upside through future royalties and partnership payment sharing.
- INFEX Therapeutics (formerly AMR Centre)minorOut-licensed MBLI/MET-X program for addressing resistant bacteria. INFEX received QIDP designation from FDA in 2023 and European patent approval in August 2023. License agreement signed with Venus Remedies Ltd for clinical development in India. Medivir entitled to share of potential future revenue.
- GlaxoSmithKlinecoreOut-licensed Xerclear marketing rights in Europe and rest of world (excluding China, Israel and South America where Medivir retained rights). Medivir receives royalties on sales of Xerclear/Zoviduo from GSK.
- Shijiazhuang Yuanmai Biotechnology Co Ltd (SYB)minorOut-licensed Xerclear rights for China market. After market registration and production in China, Medivir receives fixed royalty for each unit sold with guaranteed minimum sales during first three years on market.
Scale indicators13 records
Recent moves6 records
Expansion highlights5 records
Medivir competitors and assessment
Company assessmentMarket position
Strengths4 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Medivir social profiles
Digital presenceMedivir compliance and trust
Trust signalCompliance5 records
Medivir financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medivir leadership team
Management profileNumber of profiles
Profiles8 records
Medivir funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medivir M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medivir
What does Medivir do?
Medivir is a clinical-stage pharmaceutical company that develops proprietary drug candidates in oncology and rare bone diseases, with lead assets fostrox (a liver-targeted nucleotide DNA polymerase inhibitor prodrug for hepatocellular carcinoma) and MIV-711 (a cathepsin K inhibitor for osteogenesis imperfecta and Legg-Calvé-Perthes disease). It also maintains a portfolio of out-licensed drug assets (Xerclear for labial herpes, Remetinostat for skin cancers, Birinapant for solid tumors, MBLI/MET-X for resistant bacteria, MIV-701/VBX-1000 for veterinary periodontitis, USP-7) that generate royalties and milestone payments from pharmaceutical partners.
Is Medivir a public or private company?
Medivir is a public company. It is classified as public and is currently operating.
When was Medivir founded?
Medivir was founded in 1988. It employs 101 to 250 people.
Where is Medivir based?
Medivir is headquartered in Stockholm, Sweden, in the Europe region.
How does Medivir make money?
Five revenue lines are on record. Royalties from Xerclear/Zoviduo is the primary driver. The others are remetinostat licensing deal milestones and royalties, MIV-701/VBX-1000 royalties, MBLI/MET-X revenue sharing and USP-7 revenue sharing.
Does Medivir have an API?
No public API is recorded for Medivir.
What industry is Medivir in?
Medivir's product category is Pharmaceutical Drug Development. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 3254 and its SIC code is 2834.